|
|
xiii | |
Foreword |
|
xvii | |
Acknowledgment |
|
xix | |
|
|
1 | (6) |
|
|
|
|
Translational research and neurosciences |
|
|
1 | (2) |
|
|
3 | (4) |
|
2 Basic principles of translational research |
|
|
7 | (18) |
|
|
|
Introduction to translational research |
|
|
7 | (1) |
|
What is translational research? |
|
|
7 | (2) |
|
History of translational research |
|
|
9 | (2) |
|
Current concepts and domains |
|
|
11 | (3) |
|
|
14 | (3) |
|
Ethical issues in T1: embryonic stem cells and induced pluripotent stem cells |
|
|
17 | (1) |
|
Ethical issues in T2: artificial red blood cell products |
|
|
17 | (1) |
|
Ethical issues in T3--4: the thalidomide drug incident |
|
|
18 | (1) |
|
|
19 | (1) |
|
|
20 | (1) |
|
|
21 | (4) |
|
3 Anesthetics and translational research |
|
|
25 | (16) |
|
|
|
25 | (1) |
|
Induction and emergence from anesthesia processes |
|
|
26 | (1) |
|
|
26 | (2) |
|
Applicability clinical practice |
|
|
28 | (1) |
|
Anesthetics and consciousness: the "awareness" paradox |
|
|
29 | (2) |
|
General anesthetics and neurodegenerative processes |
|
|
31 | (2) |
|
Impact on carcinogenic processes |
|
|
33 | (1) |
|
|
34 | (1) |
|
|
35 | (1) |
|
|
35 | (6) |
|
4 Neurotoxicity and translational research |
|
|
41 | (18) |
|
|
|
|
|
|
|
|
41 | (1) |
|
Preclinical evidence and the use of animal models |
|
|
42 | (1) |
|
|
42 | (1) |
|
|
43 | (1) |
|
|
44 | (1) |
|
Anesthesia and neurotoxicity: mechanisms |
|
|
44 | (2) |
|
From laboratory to clinical trials: evidence in humans |
|
|
46 | (2) |
|
Exposure to anesthesia and the elderly |
|
|
48 | (1) |
|
Neuroprotective strategies in the perioperative setting |
|
|
49 | (1) |
|
|
50 | (1) |
|
|
50 | (1) |
|
|
50 | (1) |
|
Modulation of TNF-alpha expression |
|
|
51 | (1) |
|
|
51 | (1) |
|
Anesthesia and neurotoxicity: future experimental modalities |
|
|
52 | (1) |
|
|
52 | (1) |
|
Translational biomarkers of neurotoxicity |
|
|
52 | (1) |
|
|
52 | (1) |
|
|
53 | (6) |
|
5 Neuromonitoring and translational research |
|
|
59 | (22) |
|
|
|
|
|
|
59 | (1) |
|
|
59 | (1) |
|
|
59 | (1) |
|
Combined GCS-pupils score |
|
|
60 | (1) |
|
Full Outline of Unresponsiveness score |
|
|
60 | (1) |
|
For aneurysmal subarachnoid hemorrhage patients |
|
|
60 | (3) |
|
For ischemic stroke patients |
|
|
63 | (1) |
|
|
64 | (1) |
|
Noncontrast computerized tomography |
|
|
64 | (2) |
|
Perfusion computerized tomography |
|
|
66 | (1) |
|
Intracranial pressure and derived indices |
|
|
67 | (1) |
|
External ventricular catheters |
|
|
67 | (1) |
|
Parenchymal microtransducer devices |
|
|
67 | (1) |
|
|
67 | (1) |
|
|
67 | (1) |
|
|
68 | (1) |
|
Optic nerve sheath diameter |
|
|
68 | (1) |
|
|
69 | (1) |
|
|
69 | (1) |
|
Thermal diffusion flowmetry |
|
|
70 | (1) |
|
Jugular venous oxygen saturation |
|
|
71 | (1) |
|
Brain tissue oxygen partial pressure |
|
|
72 | (1) |
|
Near infrared spectroscopy |
|
|
73 | (1) |
|
Brain metabolism and biochemistry |
|
|
73 | (2) |
|
|
75 | (1) |
|
|
75 | (1) |
|
|
76 | (1) |
|
|
76 | (5) |
|
6 Cognition and translational research |
|
|
81 | (14) |
|
|
|
|
|
|
81 | (1) |
|
Cognitive dysfunctions in the perioperative period: definition and diagnosis |
|
|
81 | (2) |
|
Animal models of cognitive dysfunction in perioperative neuroscience |
|
|
83 | (2) |
|
|
85 | (2) |
|
Clinical studies investigating cognitive dysfunction in perioperative neuroscience |
|
|
87 | (1) |
|
|
87 | (1) |
|
Surgery including bleeding requiring blood transfusions |
|
|
87 | (2) |
|
Perioperative care for patients with known presurgery cognition dysfunctions |
|
|
89 | (1) |
|
Limits of translational research for inconsistencies of evidence from preclinical studies |
|
|
89 | (1) |
|
|
89 | (1) |
|
|
90 | (5) |
|
7 Geriatrics and translational research |
|
|
95 | (16) |
|
|
|
Cellular, biochemical, and molecular biology of aging |
|
|
95 | (1) |
|
Chromosome and telomere regulation |
|
|
96 | (1) |
|
|
96 | (1) |
|
Nuclear trafficking and organization |
|
|
96 | (1) |
|
|
96 | (1) |
|
|
96 | (1) |
|
Unfolded protein response |
|
|
96 | (1) |
|
|
97 | (1) |
|
Mitochondrial function, biogenesis, and mitophagy |
|
|
97 | (1) |
|
|
97 | (1) |
|
Replicative aging senescence and renewal |
|
|
97 | (1) |
|
Physiology, immunology, and endocrinology of aging |
|
|
97 | (1) |
|
Physiological changes: changes in nervous system |
|
|
97 | (2) |
|
Mechanisms and intervention of cellular senescence and stem cell aging |
|
|
99 | (1) |
|
Computational and functional genomics of aging |
|
|
99 | (1) |
|
Animal models of aging research |
|
|
99 | (3) |
|
Geroprotectors as antiaging chemicals |
|
|
102 | (1) |
|
Primary criteria for potential geroprotectors |
|
|
102 | (1) |
|
Secondary criteria for potential geroprotectors |
|
|
102 | (1) |
|
Classification of geroprotectors |
|
|
102 | (3) |
|
Human experiments on longevity |
|
|
105 | (1) |
|
Utility of epigenetic clock in aging and age-related diseases |
|
|
106 | (1) |
|
|
107 | (1) |
|
|
107 | (4) |
|
8 Pediatrics and translational research |
|
|
111 | (10) |
|
|
|
|
|
111 | (1) |
|
Preclinical research on perioperative anesthetics neurotoxicity |
|
|
111 | (3) |
|
Clinical research on perioperative anesthetics neurotoxicity in children |
|
|
114 | (2) |
|
Reasons for discrepancy between preclinical and clinical data |
|
|
116 | (1) |
|
|
117 | (1) |
|
|
118 | (3) |
|
9 Stroke and translational research |
|
|
121 | (18) |
|
|
Animal models for ischemic stroke |
|
|
122 | (1) |
|
Model for stroke risk factors |
|
|
123 | (1) |
|
Hyperglycemia and obesity |
|
|
123 | (3) |
|
|
126 | (1) |
|
|
126 | (1) |
|
|
127 | (1) |
|
|
127 | (1) |
|
Regeneration in stroke and neuronal repair |
|
|
128 | (1) |
|
|
129 | (1) |
|
|
130 | (1) |
|
|
130 | (1) |
|
|
130 | (9) |
|
10 Traumatic brain injury and translational research: pharmacological and nonpharmacological perspectives |
|
|
139 | (16) |
|
|
|
|
|
139 | (1) |
|
Pathophysiology of traumatic brain injury |
|
|
139 | (2) |
|
|
141 | (1) |
|
Pharmacological interventions in traumatic brain injury |
|
|
141 | (4) |
|
Nonpharmacological interventions in traumatic brain injury |
|
|
145 | (3) |
|
|
148 | (1) |
|
|
148 | (1) |
|
|
148 | (1) |
|
|
148 | (1) |
|
|
148 | (7) |
|
11 Movement disorders and translational research |
|
|
155 | (24) |
|
|
|
|
|
Etiology, diagnosis, and monitoring |
|
|
155 | (1) |
|
|
155 | (9) |
|
In prevention and treatment |
|
|
164 | (8) |
|
|
172 | (1) |
|
|
172 | (7) |
|
12 Epilepsy and translational research |
|
|
179 | (10) |
|
|
|
179 | (1) |
|
|
180 | (1) |
|
History and neurologic examination |
|
|
180 | (1) |
|
Neurophysiological examinations |
|
|
180 | (1) |
|
|
180 | (1) |
|
Other neuroimaging techniques |
|
|
181 | (1) |
|
|
181 | (1) |
|
|
181 | (1) |
|
|
182 | (1) |
|
Future perspective of translational research |
|
|
183 | (3) |
|
|
186 | (3) |
|
13 Translational research in delayed cerebral ischemia |
|
|
189 | (14) |
|
|
|
|
|
189 | (1) |
|
Experimental aneurysmal subarachnoid hemorrhage |
|
|
189 | (1) |
|
Characteristics of experimental SAH models |
|
|
190 | (1) |
|
Perspectives on the current status of SAH animal models |
|
|
190 | (2) |
|
Failure in current SAH studies |
|
|
192 | (1) |
|
|
193 | (1) |
|
Delayed cerebral vasospasm: from extravascular blood to vessel lumen |
|
|
193 | (1) |
|
Microcirculatory spasm and dysfunction |
|
|
194 | (1) |
|
Microthrombosis: an additional explanation for DCI |
|
|
195 | (1) |
|
Cortical spreading ischemia |
|
|
196 | (1) |
|
Are we close to solving the mystery of SAH? |
|
|
196 | (1) |
|
|
197 | (1) |
|
|
197 | (1) |
|
|
197 | (6) |
|
14 Translation research in pain medicine |
|
|
203 | (12) |
|
|
|
|
|
203 | (1) |
|
|
204 | (1) |
|
|
204 | (1) |
|
|
205 | (1) |
|
Models in pain management |
|
|
205 | (1) |
|
|
205 | (1) |
|
Interventional management |
|
|
205 | (1) |
|
|
206 | (1) |
|
|
207 | (1) |
|
Immense opportunity for translational research in pain medicine |
|
|
208 | (1) |
|
Bridging the gap between pain research and clinical pain management |
|
|
208 | (2) |
|
Analyzing current theories of pain mechanisms and their relevance to clinical pain |
|
|
210 | (1) |
|
Exploring new tools for both preclinical and clinical pain research |
|
|
210 | (1) |
|
|
211 | (4) |
|
15 Ethical considerations in translational research |
|
|
215 | (10) |
|
|
|
215 | (1) |
|
Evolution of translational research ethics |
|
|
215 | (1) |
|
|
216 | (1) |
|
Declaration of Helsinki (1964) |
|
|
216 | (1) |
|
|
216 | (1) |
|
The Belmont Report (1979) |
|
|
217 | (1) |
|
|
217 | (1) |
|
International ethical guidelines |
|
|
217 | (1) |
|
Ethical considerations in translational research |
|
|
218 | (1) |
|
High-quality preclinical research |
|
|
218 | (1) |
|
|
219 | (1) |
|
Therapeutic misconception |
|
|
220 | (1) |
|
|
220 | (1) |
|
|
221 | (1) |
|
|
221 | (1) |
|
International collaboration |
|
|
222 | (1) |
|
Commercialization of translational research |
|
|
222 | (1) |
|
Ethical issues in vulnerable neurological population |
|
|
222 | (3) |
Summary |
|
225 | (1) |
References |
|
225 | (4) |
Index |
|
229 | |